Sanofi Dupixent gets USFDA nod for bullous pemphigoid treatment in adults Ruchika Sharma20 Jun 2025 12:15 PM ISTParis: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment of adult patients...
Sanofi successfully prices euro 1.5 billion bond issue Ruchika Sharma18 Jun 2025 10:00 AM ISTParis: Sanofi has successfully priced its offering of euro 1.5 billion of notes across 2 tranches:€750 million fixed-rate notes, due June 2029,...
Sanofi-Regeneron Dupixent data reinforce use in atopic dermatitis patients with skin of color Ruchika Sharma9 Jun 2025 1:12 PM ISTParis: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent (dupilumab) in adults and...
Sanofi launches 2025 Global Employee Stock Purchase Plan Ruchika Sharma8 Jun 2025 12:30 PM ISTParis: Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries.In 2024 alone,...
Sanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell disease Ruchika Sharma4 Jun 2025 1:30 PM ISTParis: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, advanced, oral,...
Sanofi to acquire Blueprint Medicines for up to USD 9.5 billion Ruchika Sharma3 Jun 2025 3:23 PM ISTParis: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis...
Itepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron Ruchika Sharma1 Jun 2025 3:00 PM ISTParis: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic...
Sanofi broadens immunology pipeline with acquisition of DR-0201 Ruchika Sharma27 May 2025 11:00 AM ISTParis: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private...
Sanofi India ropes in Sudipta Chakraborty as Head of Legal, India Ruchika Sharma26 May 2025 2:30 PM ISTMumbai: Sanofi India has announced the appointment of Sudipta Chakraborty as the Head of Legal, India, effective from 2nd June 2025."We wish to inform...
CDSCO Panel Approves Fabrazyme Label Update, Asks Sanofi to Submit EMA Nod Dr. Divya Colin25 May 2025 3:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to Sanofi Healthcare...
Sanofi to buy Vigil Neuroscience in USD 470 million deal Ruchika Sharma22 May 2025 12:33 PM ISTParis: Sanofi has announced that it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage...
Sanofi sells controlling stake of consumer healthcare business Opella Ruchika Sharma2 May 2025 3:35 PM ISTParis: Sanofi has announced the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi...
